News from 3CTN  |  July 2020 Issue                           View this in your browser
3CTN receives funding from Canadian Partnership Against Cancer to improve cancer clinical trials participation for under served patients 
Last month, the Canadian Partnership Against Cancer (CPAC, the Partnership) formally announced the funding commitment through 2022 to support 3CTN’s new initiative to increase cancer clinical trial access for cancer patients in the pediatric and adolescent and young adults (AYA) population and those in remote and rural communities. The funding of almost $1 million aims to increase clinical trials participation for underserved patients through:
  1. Engagement and support for C17 pediatric oncology network to help advance pediatric and AYA clinical trials and research to ensure this patient population has access to appropriate trials,  and;
  2. Development and implementation of the CRAFTCanadian Remote Access Framework for Clinical Trials position paper to expand trial opportunities for patients in rural and remote communities.
Read announcement
Implementing the CRAFT
The development of the CRAFT position paper made the case for expanded clinical trial access across Canada and presented the model approach for establishing “trial clusters” of remote satellite sites as extensions of a Cancer Centre primary site. The recently-announced CPAC funding commitment provides for 3CTN to plan for, launch and evaluate proof of concept trials by identified trial clusters. 
This year will focus on evaluation planning and forming working groups to guide development of template agreements and tools for supporting Cancer Centres’ use in making risk-based determinations of trial activities as well as supervision and training required for remote research conducted by statellite site health professionals. A Request for Proposal process to select trials and clusters for piloting the CRAFT will be completed prior to launching Proof of Concept trials next year.

If you are interested in being part of the CRAFT project, please let us know by emailing
Network Centres adapt and utilize EDGE during COVID-19
The COVID-19 pandemic has presented challenges to clinical research activities and Network centres were forced to adapt to changes rapidly. At the onset, as institutions responded with trial unit closures and staff redeployments, site teams were required to review operating capacity, triage all trial activities and assess status and case management for patients involved in open trials as well as those put on hold. For Network centres using EDGE CTMS, this job was made easier. As a web-based application EDGE made it easier for study personnel working remotely to continue to track and manage clinical trials activities.
In March, EDGE added three new trial status options to capture COVID-19 impact:
  • Setup on hold - COVID-19
  • Recruitment on hold - COVID-19
  • Follow up on hold - COVID-19
These options enabled sponsors and centres to identify those trials directly affected by COVID-19. A majority of Network centres using EDGE have adopted the special status for keeping track of trials and related patients. By tracking the information gathered by centres within EDGE, the 3CTN Coordinating Centre was able to determine that approximately 70% of academic Portfolio trials were placed on hold. 

The availability of aggregate Network level data, in turn, will be greatly beneficial in evaluating pandemic impacts including current-year recruitment projections.  
Interactive reports with MS Power BI
Over the past year, the 3CTN Portfolio team has been moving reports from MS Excel to MS Power BI. The goal of the interactive Power BI reports is to showcase success across the Network and help inform decision-making. With the generation of five main Power BI reports we have seen the power and effectiveness of Power BI as a reporting and data analysis tool and aim to share our experience with the Network. 3CTN’s current Power BI reports can be found in the 3CTN Reports and Trial Portfolio pages. The Portfolio team continues to provide stakeholder demos and tutorials on report navigation.
Register for sessions
ASCO Survey on early impact of COVID-19 on the performance of oncology clinical trials
In early May, ASCO conducted a survey of clinical programs exploring the early impact of the COVID-19 pandemic on the performance of oncology clinical trials. Results from the survey highlighted the numerous issues faced by cancer programs, adaptive measures taken in response and the potential for beneficial changes in trials conduct beyond the current crisis.
Read article
It’s here! The newly redesigned 3CTN website
After months of planning and hard work, we are thrilled to announce our newly-redesigned website! The new website focuses on providing our stakeholders an easier way to learn about 3CTN through improved aesthetics, simplified content and new resources.

For example, the newly added Explore the Network feature’s interactive graphics and filter criteria allows users to find a 3CTN Cancer Centre or Portfilio trial of interest across Canada by province, disease site, trial impact category or other defined criteria of interest.

The new design includes streamlined and clear navigation menus, easy to locate Recruitment and PPI tools, as well as resources and videos about patients’ experiences.
Explore website
NACC Spotlight: BC Cancer-Victoria
In early 2019, the team at BC Cancer – Victoria NACC launched the ‘Innovative Therapies & Precision Medicine Program’ to enhance research and treatment options for cancer patients on Vancouver Island. At the time of program launch there were six clinical trials available, as of June 2020 there are now 12 clinical trials open to recruitment with a further seven trials slated to open before the end of the year. There was also a noticeable 16 percent increase in the number of patients enrolling in clinical trials in Victoria in the program’s first year. Philip Pollock, Manager of Clinical Trials & Clinical Research, says, “our vision for this program is to offer all patients walking into our centre a clinical trial option for their cancer regardless of tumour origin and stage.”  

In the fall of 2019, a new set of SOPs for clinical trials was launched including new procedures supporting its overall Quality Management Plan governing document management, training, audits, deviation reporting, corrective/preventative action plans, as well as vendor qualification and surveillance.
Highlighting PPI at 3CTN - Patient Partners in Clinical Trials
Jill Hammer-Wilson talks about her patient experience and the importance of patient participation in clinical trials. 
Watch video
Celebrating International Clinical Trials Day
Each year, International Clinical Trials Day (ICTD) is held on May 20 to commemorate the day Dr. James Lind began his pioneering investigation into the causes of scurvy in 1747 that laid the foundation for modern clinical trials. This year, in light of COVID-19, Network centres were encouraged to celebrate and share ICTD messaging virtually. Some of the Network centres held online events to raise patient, public and institutional awareness about clinical trials and research happening at their centres.

Following their respective ICTD events, teams shared highlights with the Network:
In Quebec, Q-CROC launched an online clinical research awareness campaign entitled, "In 2020, I Discover Clinical Research”, with the goal of widely sharing oncology clinical research across Quebec’s cancer centres and its stakeholders. A page was created on Q-CROC’s website providing basic information about clinical trials and patient testimonials. A secondary page highlighted statistics on Quebec's clinical research activities, for example, number of clinical trials participants in 2019. Several centres and patient associations and groups across Quebec promoted the campaign through their social media platforms.
View the campaign page:
In Ontario, NACC-Grand River Hospital celebrated by taking over the hospital’s Instragram account for the entire day. The Instagram stories featured departments and staff and included laboratory, pharmacy, oncology, study coordinators, physicians and others to highlight the manifold roles involved in the conduct of clinical trials. NACC team member, Ms. Carla Girolametto spearheaded the Instagram event and reflected, “With COVID-19, we were challenged to think out of the box and find a creative way to raise awareness of clinical trials. It was such a great experience to virtually showcase the work we do at Grand River Hospital to support clinical trials.”
OncoQuebec website recognized in Desjardins “Stars of the health network” contest
Launched in October 2019 by Quebec Clinical Research Organization in Cancer, OncoQuebec is a web-based application to search for oncology clinical trials in the province of Quebec. It is an intuitive search system that meets the needs of providers, patients and their loved ones. In June 2020, the application won third place in the Desjardins “Stars of the health network” contest. OncoQuebec distinguished itself in the category, “Simple: simplifies tasks or processes and improves the way things are done in health network institutions”. More recently, additional improvements were made to the application to further facilitate trials search including:
  • Multicentred studies now appear only once in the results list.
  • Biomarkers have been added to the new studies fact sheet.
  • Recently added trials are prominently displayed on the home page.
Search for trials
Stakeholder engagement on ICH GCP
In early June, the Clinical Trials Transformation Initiative (CTTI) in collaboration with U.S. Food and Drug Administration, held a two-day public web conference to report on the stakeholder engagement process for informing future revisions to the International Council for Harmonisation’s Good Clinical Practice guidelines E6(R2).
Watch presentations
Key dates ahead

July 16                Power BI Advanced Features
August 17           Year 7, Q2 Reports Due
September 25    3CTN Portfolio Complexity & Per Case Funding Calculations
Do you have news to share?
Be featured in the next issue of 3CTN's Network Pulse by submitting a brief (~150 word) story along with pictures to
Copyright © 2020 Canadian Cancer Clinical Trials Network, All rights reserved.
You are receiving this email because you are signed up to receive 3CTN's Quarterly Newsletter or because you are affiliated with the Network.

Our mailing address is:
Canadian Cancer Clinical Trials Network
MaRS Centre
661 University Ave, Suite 510
Ontario, Canada 
M5G 0A3

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Canadian Cancer Clinical Trials Network · 661 University Ave · Suite 501 · Toronto, On M5G0A3 · Canada

Email Marketing Powered by Mailchimp